4.2 Article

Incidence of and risk factors for interstitial pneumonia in patients with rheumatoid arthritis in a large Japanese observational cohort, IORRA

Journal

MODERN RHEUMATOLOGY
Volume 20, Issue 3, Pages 280-286

Publisher

TAYLOR & FRANCIS LTD
DOI: 10.1007/s10165-010-0280-z

Keywords

Rheumatoid arthritis; Interstitial pneumonia; Incidence; Risk factor; Methotrexate

Categories

Funding

  1. Abbott Japan Co., Ltd.
  2. Asahikasei Kuraray Medical Co., Ltd.
  3. Asahikasei Pharma Corporation
  4. Astellas Pharma Inc.
  5. AstraZeneca K.K.
  6. Banyu Pharmaceutical Co., Ltd.
  7. Chugai Pharmaceutical Co., Ltd.
  8. Daiichi Fine Chemical Co., Ltd.
  9. Daiichi Sankyo Co., Ltd.
  10. Dainippon Sumitomo Pharma Co., Ltd.
  11. Eisai Co., Ltd.
  12. GlaxoSmithKline K.K.
  13. Janssen Pharmaceutical K.K.
  14. Japan Tobacco Inc.
  15. Kaken Pharmaceutical Co., Ltd.
  16. Kissei Pharmaceutical Co., Ltd.
  17. Kowa Pharmaceutical Co., Ltd.
  18. Mitsubishi Chemical Medience Corporation
  19. Mitsuibishi Tanabe Pharma Corporation
  20. Nippon Chemiphar Co., Ltd.
  21. Nippon Shinyaku Co., Ltd.
  22. Novartis Pharma K.K.
  23. Otsuka Pharmaceutical Co., Ltd.
  24. Pfizer Japan Inc.
  25. Sanofi-Aventis K.K
  26. Santen Pharmaceutical Co., Ltd.
  27. Sanwa Kagaku Kenkyusho Co., Ltd.
  28. Sekisui Medical Co., Ltd.
  29. Taisho Toyama Pharmaceutical Co., Ltd.
  30. Takeda Pharmaceutical Company Limited
  31. Teijin Pharma Limited
  32. Torii Pharmaceutical Co., Ltd.
  33. Toyama Chemical Co., Ltd.
  34. UCB Japan Co., Ltd.
  35. Wyeth K.K.
  36. Zeria Pharmaceutical Co., Ltd.

Ask authors/readers for more resources

Interstitial lung disease (ILD) is a frequently encountered and sometimes life-threatening complication among patients with rheumatoid arthritis (RA). In this study, we aim to clarify the incidence of and risk factors for ILD using a large observational cohort of RA patients. We analyzed the database from a large observational cohort of Japanese RA patients, the Institute of Rheumatology, Rheumatoid Arthritis (IORRA) cohort. We defined as interstitial pneumonia (IP) computed tomography (CT) pattern of nonspecific interstitial pneumonia or diffuse alveolar damage. Newly developed IP was identified from patient reports over 2.5 years (April 2004 to October 2006) and was confirmed by extensive medical record, chest X-ray radiograph, and CT. The raw and age/gender-adjusted incidence of IP were reported. IP risk factors were analyzed using a nested case-control design was employed using conditional logistic regression analysis with a stepwise method. Thirty-seven patients among 5,699 RA patients were diagnosed with newly developed IP, including 18 cases with methotrexate-induced pneumonitis (MTX-IP) and 15 cases with IP associated with RA (RA-IP). The age-adjusted incidence of MTX-IP among total patients, males, and females was 3.775, 6.667, and 1.013 per 1,000 cases, respectively, and of RA-IP among total patients, males, and females was 1.056, 1.452, and 0.677 per 1,000 cases, respectively. Conditional logistic regression analysis after stepwise variable selection identified male gender, increased Japanese version of the Health Assessment Questionnaire (J-HAQ) score, decreased pain visual analog scale (VAS), and elevated erythrocyte sedimentation rate as significant risk factors for MTX-IP, while the only risk factor for RA-IP was male gender. The incidence of and risk factors for IP in RA patients were determined in a large observational cohort of RA patients in Japan.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available